Balloon Dilator — Urethral, Ureteral, BNC, Prostatic
Balloon dilation applies radial expansion across a narrowed lumen. The label covers several devices that are not interchangeable: plain urethral dilation balloons, ureteral dilation balloons, the Optilume urethral drug-coated balloon (DCB), and the separate Optilume BPH two-catheter system. Material, wire size, balloon diameter, rated burst pressure, inflation time, drug dose, and catheter management are device-specific; use the selected product's current instructions for use (IFU).[1][4][6]
This is the instrument-level overview. Indications, treatment selection and outcome data are on the linked procedure pages.
Device Families
| Family | Defining features | Important boundary |
|---|---|---|
| Plain urethral balloon | Balloon catheter positioned across a urethral stricture and inflated under endoscopic and/or fluoroscopic control | Designs, diameters, pressures, and hold times vary by manufacturer; do not transfer a protocol between products |
| Plain ureteral balloon | Small-caliber over-the-wire balloon used in upper-tract endourology | Ureteral and urethral balloons have different dimensions and indications |
| Optilume urethral DCB | Semi-compliant paclitaxel-coated balloon, compatible with a 0.038-inch guidewire; FDA labeling lists 18, 24, 30, and 36 Fr diameters and 30- or 50-mm balloon lengths | FDA indication and the AUA recommendation are for selected male anterior/bulbar stricture disease, not every urethral narrowing[4][5] |
| Optilume BPH | Separate system using a pre-dilation catheter and a double-lobe paclitaxel-coated balloon catheter | It is a prostatic-urethra system with its own indication, contraindications, sizing, and IFU; it is not the urethral-stricture DCB[6] |
The Optilume urethral DCB carries paclitaxel at 3.5 µg/mm². It is semi-compliant and rated to 12 atm (18 and 24 Fr), 10 atm (30 Fr) or 8 atm (36 Fr). The label calls for 60 seconds of hydration in the urethra before inflation and at least 5 minutes of inflation, with a 0.038-inch or smaller guidewire.[4] Not every balloon is non-compliant PET or polyethylene, and not every platform accepts a 0.035-inch wire.
Radial Versus Axial Dilation
| Feature | Balloon dilator | Metal sound or coaxial dilator |
|---|---|---|
| Force vector | Radial, perpendicular to the lumen | Axial, along the lumen |
| Guidance | Endoscopic or fluoroscopic, wire-guided | Tactile, or over a wire |
| Drug delivery | Possible (Optilume) | Not possible |
| Setup | Wire, balloon, pressure-gauge inflator, imaging | Lubricant and sound |
| Cost | Single-use; drug-coated devices cost more | Reusable, low |
Mechanism and Placement
A balloon expands radially at the treatment site, whereas sequential sounds and coaxial dilators are advanced axially through the narrowing. Direct visualization or fluoroscopy can show position and balloon-waist behavior, but a wire-guided balloon is not risk-free: false passage, perforation, bleeding, infection, and recurrent narrowing remain possible.
Typical workflow, adapted to the selected device and anatomy:
- Define the narrowing and establish true-lumen access under cystoscopic, ureteroscopic, and/or fluoroscopic guidance.
- Confirm that the wire is in the intended cavity before advancing a balloon.
- Center the working balloon across the narrowing.
- Inflate only to the pressure, diameter, duration, and number of inflations specified by the device IFU or study protocol.
- Confirm luminal access after deflation and choose a catheter or stent plan based on the procedure, mucosal injury, and selected device.
Gelman and colleagues described a purpose-built system that permits urethral balloon dilation under direct vision; that short technical report supports the visualization concept, not a universal claim of lower injury or superior durability versus every alternative.[1]
Reconstructive-Urology Uses
| Site | Instrument role | Canonical WARWIKI page |
|---|---|---|
| Male anterior/bulbar urethra | Plain dilation or, in selected recurrent disease, urethral DCB. In ROBUST III (recurrent anterior strictures shorter than 3 cm), freedom from reintervention at 1 year was 83.2% with DCB versus 21.7% with dilation or DVIU[2][5] | DVIU and Urethral Dilation · Drug-Coated Balloon Therapy |
| Female urethra | Selected short narrowing managed endoscopically | Female DVIU / Dilation |
| Bladder neck / VUAS | Balloon dilation alone (59% success, 16 of 27, in one 1994 series with no new incontinence) or as an initial step before incision[3] | Balloon Dilation for BNC |
| Prostatic urethra | Optilume BPH system for labeled BPH use | Optilume BPH · Optilume BPH (biomaterials) |
| Ureter / UPJ / ureteroenteric anastomosis | Plain endourologic balloon in selected benign strictures; drug-coated ureteral use remains off-label/investigational | Balloon Dilation (Upper Tract) |
The 2023 AUA amendment states that surgeons may offer urethral DCB with dilation or DVIU for recurrent bulbar strictures shorter than 3 cm (conditional recommendation, Grade B). That is narrower than a blanket indication for anterior, penile, radiation-associated, or previously untreated strictures.[5]
Practical Boundaries
- Follow the actual IFU. Rated burst pressure, inflation time, compatible wire, preparation, drug-handling precautions, catheter duration, and contraindications are product-specific.
- Do not infer safety from radial force alone. True-lumen confirmation and atraumatic positioning matter more than a simple balloon-versus-sound ranking.
- Do not transfer outcomes between anatomic sites or products. A urethral DCB trial does not validate a plain ureteral balloon, and Optilume BPH data do not validate urethral-stricture treatment.
- Plain dilation does not remove spongiofibrosis. Recurrence depends on site, length, etiology, prior treatment, tissue quality, and the definitive reconstructive options.
- DCB is not a universal substitute for reconstruction. Long, penile, ischemic, radiation-associated, and repeatedly recurrent disease requires disease-specific evaluation.
- Antimicrobial prophylaxis is not an instrument property. Use the applicable procedure, urine-culture, and institutional guidance rather than a blanket balloon rule.
Related Instruments
- Guidewires: true-lumen access and support.
- S-Shaped Coaxial Dilators: wire-guided sequential urethral dilation.
- Filiforms & Followers: legacy leader-and-follower system.
- Van Buren Sound and Hegar Dilators: non-balloon mechanical dilators.
References
1. Gelman J, Liss MA, Cinman NM. Direct vision balloon dilation for the management of urethral strictures. J Endourol. 2011;25(8):1249–1251. doi:10.1089/end.2011.0034
2. Elliott SP, Coutinho K, Robertson KJ, et al. One-year results for the ROBUST III randomized controlled trial evaluating the Optilume drug-coated balloon for anterior urethral strictures. J Urol. 2022;207(4):866–875. doi:10.1097/JU.0000000000002346
3. Ramchandani P, Banner MP, Berlin JW, Dannenbaum MS, Wein AJ. Vesicourethral anastomotic strictures after radical prostatectomy: efficacy of transurethral balloon dilation. Radiology. 1994;193(2):345–349. doi:10.1148/radiology.193.2.7972741
4. Urotronic, Inc. Optilume Urethral Drug Coated Balloon Catheter System: Instructions for Use. FDA PMA P210020; 2021.
5. American Urological Association. Urethral Stricture Guideline Amendment Summary. 2023.
6. Urotronic, Inc. Optilume BPH Catheter System: Instructions for Use. FDA PMA P220029; 2025.